Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene FGFR2
Variant G183fs
Impact List frameshift
Protein Effect loss of function - predicted
Gene Variant Descriptions FGFR2 G183fs results in a change in the amino acid sequence of the Fgfr2 protein beginning at aa 183 of 821, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), G183fs is predicted to lead to a loss of Fgfr2 protein function.
Associated Drug Resistance
Category Variants Paths

FGFR2 mutant FGFR2 exon5 FGFR2 G183fs

FGFR2 mutant FGFR2 inact mut FGFR2 G183fs

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_000141.5
gDNA chr10:g.(121551367_121551368)
cDNA c.(547_546)
Protein p.G183fs
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
NM_001144915.2 chr10:g.(121520104_121520105) c.(547_546) p.G183fs RefSeq GRCh38/hg38
NM_023029.2 chr10:g.(121520104_121520105) c.(547_546) p.G183fs RefSeq GRCh38/hg38
NM_001144914.1 chr10:g.(121551367_121551368) c.(547_546) p.G183fs RefSeq GRCh38/hg38
NM_001320658.2 chr10:g.(121551367_121551368) c.(547_546) p.G183fs RefSeq GRCh38/hg38
NM_022970 chr10:g.(121551367_121551368) c.(547_546) p.G183fs RefSeq GRCh38/hg38
NM_001144918 chr10:g.(121520026_121520027) c.(547_546) p.G183fs RefSeq GRCh38/hg38
NM_001144916 chr10:g.(121520026_121520027) c.(547_546) p.G183fs RefSeq GRCh38/hg38
NM_022970.4 chr10:g.(121551367_121551368) c.(547_546) p.G183fs RefSeq GRCh38/hg38
NM_001144913 chr10:g.(121551367_121551368) c.(547_546) p.G183fs RefSeq GRCh38/hg38
NM_023029 chr10:g.(121520104_121520105) c.(547_546) p.G183fs RefSeq GRCh38/hg38
NM_022970.3 chr10:g.(121551367_121551368) c.(547_546) p.G183fs RefSeq GRCh38/hg38
NM_001144919.1 chr10:g.(121520104_121520105) c.(547_546) p.G183fs RefSeq GRCh38/hg38
NM_001144915.1 chr10:g.(121520104_121520105) c.(547_546) p.G183fs RefSeq GRCh38/hg38
NM_000141.4 chr10:g.(121551367_121551368) c.(547_546) p.G183fs RefSeq GRCh38/hg38
NM_001144919.2 chr10:g.(121520104_121520105) c.(547_546) p.G183fs RefSeq GRCh38/hg38
NM_023029.2 chr10:g.(121520104_121520105) c.(547_546) p.G183fs RefSeq GRCh38/hg38
NM_001144913.1 chr10:g.(121551367_121551368) c.(547_546) p.G183fs RefSeq GRCh38/hg38
NM_001144919 chr10:g.(121520104_121520105) c.(547_546) p.G183fs RefSeq GRCh38/hg38
NM_001144913.1 chr10:g.(121551367_121551368) c.(547_546) p.G183fs RefSeq GRCh38/hg38
NM_001144918.2 chr10:g.(121520026_121520027) c.(547_546) p.G183fs RefSeq GRCh38/hg38
NM_001144917.1 chr10:g.(121551367_121551368) c.(547_546) p.G183fs RefSeq GRCh38/hg38
NM_001144917.2 chr10:g.(121551367_121551368) c.(547_546) p.G183fs RefSeq GRCh38/hg38
NM_000141 chr10:g.(121551367_121551368) c.(547_546) p.G183fs RefSeq GRCh38/hg38
NM_001144915 chr10:g.(121520104_121520105) c.(547_546) p.G183fs RefSeq GRCh38/hg38
NM_001320658.1 chr10:g.(121551367_121551368) c.(547_546) p.G183fs RefSeq GRCh38/hg38
NM_001320658 chr10:g.(121551367_121551368) c.(547_546) p.G183fs RefSeq GRCh38/hg38
NM_001144914.1 chr10:g.(121551367_121551368) c.(547_546) p.G183fs RefSeq GRCh38/hg38
NM_001144918.1 chr10:g.(121520026_121520027) c.(547_546) p.G183fs RefSeq GRCh38/hg38
NM_001144916.2 chr10:g.(121520026_121520027) c.(547_546) p.G183fs RefSeq GRCh38/hg38
NM_001144914 chr10:g.(121551367_121551368) c.(547_546) p.G183fs RefSeq GRCh38/hg38
NM_000141.5 chr10:g.(121551367_121551368) c.(547_546) p.G183fs RefSeq GRCh38/hg38
NM_001144917 chr10:g.(121551367_121551368) c.(547_546) p.G183fs RefSeq GRCh38/hg38
NM_001144916.1 chr10:g.(121520026_121520027) c.(547_546) p.G183fs RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
FGFR2 mutant Advanced Solid Tumor predicted - sensitive Zoligratinib Phase I Actionable In a Phase I trial, Debio 1347 treatment resulted in partial response in 10.5% (6/57) and stable disease in 28.1% (16/57) of patients with advanced solid tumors harboring genomic alterations of FGFR1/2/3, including amplifications, fusions, and mutations (PMID: 30745300; NCT01948297). 30745300
FGFR2 mutant endometrial cancer sensitive PRN1371 Preclinical - Cell culture Actionable In a preclinical study, PRN1371 inhibited proliferation of endometrial cancer cells harboring FGFR2 mutations in culture (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1249). detail...
FGFR2 mutant breast cancer no benefit Sunitinib Case Reports/Case Series Actionable In a Phase II trial (TAPUR), Sutent (sunitinib) treatment did not meet the predetermined efficacy criteria in metastatic breast cancer patients with FGFR2 amplification (n=2), FGFR2 mutation (including FGFR2 rearrangement) (n=6), or both (n=2), resulting in no objective responses or stable disease of at least 16 weeks, median progression-free survival of 8 weeks, and a median overall survival of 22 weeks (PMID: 38354330; NCT02693535). 38354330
FGFR2 mutant transitional cell carcinoma predicted - sensitive Cetrelimab + Erdafitinib Phase II Actionable In a Phase II trial, the combination of Balversa (erdafitinib) and Cetrelimab (JNJ-63723283) treatment resulted in an overall response rate of 54.5% (6 complete responses), disease control rate of 79.5%, median duration of response of 11.10 months, median progression-free survival of 10.97 months, and a 12-month overall survival of 68% in patients with metastatic urothelial carcinoma harboring FGFR mutations (J Clin Oncol 41, 2023 (suppl 16; abstr 4504); NCT03473743). detail...
FGFR2 mutant Advanced Solid Tumor sensitive Pemigatinib Preclinical - Cell culture Actionable In a preclinical study, a variety of cancer cell lines harboring mutations in FGFR1, FGFR2, and/or FGFR3 demonstrated sensitivity to Pemazyre (pemigatinib) in culture and in cell line xenograft models, resulting in inhibition of tumor growth (Cancer Res 2015;75(15 Suppl):Abstract nr 771). detail...
FGFR2 mutant cholangiocarcinoma predicted - sensitive Erdafitinib Phase I Actionable In a Phase I trial, Balversa (erdafitinib) treatment resulted in an objective response rate of 27% (3/11) in patients with cholangiocarcinoma harboring FGFR genomic alterations, including 1 with FGFR2 mutation, 2 with FGFR3 mutations, and 8 with FGFR2 fusions (PMID: 31088831; NCT01703481). 31088831
FGFR2 mutant Advanced Solid Tumor predicted - sensitive ICP-192 Phase I Actionable In a Phase I trial, ICP-192 (gunagratinib) was well-tolerated, and resulted in an overall response rate or 33.3% (4/12, 1 complete response, 3 partial response) and a disease control rate of 91.7% (11/12) in patients with advanced solid tumors harboring FGF/FGFR gene aberrations (J Clin Oncol 39, 2021 (suppl 15; abstr 4092); NCT03758664). detail...
FGFR2 mutant endometrial cancer sensitive Infigratinib Preclinical Actionable In a preclinical study, Truseltiq (infigratinib) inhibited the growth of FGFR2-mutated endometrial cancer cells in vitro and in xenograft models (PMID: 23443805). 23443805
FGFR2 mutant cholangiocarcinoma sensitive Infigratinib Case Reports/Case Series Actionable In a Phase I trial, a patient with cholangiocarcinoma harboring an FGFR2 mutation demonstrated a decreased tumor burden when treated with Truseltiq (infigratinib) (PMID: 27870574). 27870574
FGFR2 mutant intrahepatic cholangiocarcinoma predicted - sensitive Derazantinib Phase II Actionable In a Phase II trial (FIDES-01), Derazantinib (ARQ 087) treatment resulted in an objective response rate of 6.5%, a disease control rate of 58.1%, median progression-free survival of 8.3 months, and a median overall survival of 15.9 months in patients with intrahepatic cholangiocarcinoma harboring an FGFR2 mutation or amplification (Ann Oncol (2022) 33 (suppl_7): S19-S26; NCT03230318). detail...
FGFR2 mutant Advanced Solid Tumor predicted - sensitive Erdafitinib Case Reports/Case Series Actionable In a Phase II trial (MATCH), Balversa (erdafitinib) treatment resulted in an objective response rate of 16% (4/25), median progression-free survival of 3.6 months, and median overall survival of 11.0 months in patients with advanced solid tumors harboring FGFR1, FGFR2, or FGFR3 mutations or fusions (PMID: 38603650; NCT02465060). 38603650